Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could muscle proteins reveal hidden muscle loss in diabetes and obesity?

NCT ID NCT07703683

Knowledge-focused Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study investigates whether proteins released by muscles, called myokines, can serve as early warning signs or even causes of muscle loss (sarcopenia) in people with metabolic or endocrine conditions like diabetes, obesity, and Cushing syndrome. Researchers will measure myokine levels in blood and muscle tissue from 100 participants and compare them to muscle health. The goal is to better understand why muscle loss occurs in these diseases and find new ways to detect or prevent it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify early biomarkers for muscle loss in metabolic diseases, paving the way for targeted treatments or prevention strategies.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly test any therapy. The findings may not lead to immediate clinical applications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2056

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People with metabolic or endocrine diseases

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Metabolic or endocrine disease Exclusion Criteria: * Known myopathy * Systemic steroid use (\> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome * Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol * History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cushing syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cushing syndrome diabetes mellitus endocrine system disorder metabolic disease Obesity obesity disorder Overweight Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cushing syndrome Diabetes Endocrine diseases Metabolic diseases Obesity & overweight Sarcopenia Sarcopenic obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cliniques Universitaires Saint-Luc

    RECRUITING

    Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, 1150, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.